Ir para o conteúdo principal

United States News Todas as matérias

Todas as matérias desta seção, das mais recentes às mais antigas — página 149 de 371.

Grafa

Verastem Oncology reports positive RAMP 205 data in front-line pancreatic cancer

Verastem Oncology (NASDAQ:VSTM) today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating its investigational combination regimen in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).

Leia mais: Verastem Oncology reports positive RAMP 205 data in front-line pancreatic cancer